Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma

Approximately 50% of melanomas harbor an activating BRAF mutation. Combined BRAF and MEK inhibitors such as dabrafenib and trametinib, vemurafenib and cobimetinib, and encorafenib and binimetinib are US Food and Drug Administration (FDA)-approved to treat patients with BRAF(V600)-mutated advanced me...

Descripción completa

Detalles Bibliográficos
Autores principales: Kakadia, Sunilkumar, Yarlagadda, Naveen, Awad, Ramez, Kundranda, Madappa, Niu, Jiaxin, Naraev, Boris, Mina, Lida, Dragovich, Tomislav, Gimbel, Mark, Mahmoud, Fade
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200076/
https://www.ncbi.nlm.nih.gov/pubmed/30410366
http://dx.doi.org/10.2147/OTT.S182721

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200076/
https://www.ncbi.nlm.nih.gov/pubmed/30410366
http://dx.doi.org/10.2147/OTT.S182721

Ejemplares similares